UCPH-101是一种兴奋性氨基酸转运蛋白亚型1（EAAT1）抑制剂，IC50值为0.66μM。
Cas No.:1118460-77-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
UCPH-101 is an inhibitor of Excitatory Amino Acid Transporter 1 (EAAT1), with an IC50 value of 0.66μM[1]. UCPH-101 acts as a slow-binding, non-competitive EAAT1 inhibitor; it blocks the translocation step within the transport cycle rather than other partial reactions[2]. UCPH-101 is capable of blocking the neuroprotective effects of dexmedetomidine and guanfacine[3]. UCPH-101 induces glioblastoma cell death by promoting the intracellular accumulation of glutamate and has been shown to significantly improve survival in mouse models of glioma[4].
In vitro, treatment of murine MA9-1 cells and human U937 cells with UCPH-101 (20μM) for 6-24 hours significantly increased apoptotic levels in both cell lines, resulting in a decrease in cells in the G1 phase and a corresponding increase in cells in the S and G2/M phases[5]. Treatment of GL261-NS cells, GBM-NS cells, and astrocytes with UCPH-101 (10μM) significantly elevated apoptotic levels in the GL261-NS and GBM-NS cells, while having no effect on the apoptotic levels of the astrocytes[6].
In vivo, intracranial administration of UCPH-101 (10nmol/μL) to mice bearing glioma xenografts significantly improved survival rates. Furthermore, the treatment significantly disrupted the tissue architecture of the brain gliomas, significantly downregulated the expression levels of the glutamate-aspartate transporter (GLAST) within the tumor tissue, and significantly upregulated the expression levels of cleaved Caspase-3[6].
References:
[1] Huynh T H V, Abrahamsen B, Madsen K K, et al. Design, synthesis and pharmacological characterization of coumarin-based fluorescent analogs of excitatory amino acid transporter subtype 1 selective inhibitors, UCPH-101 and UCPH-102[J]. Bioorganic & medicinal chemistry, 2012, 20(23): 6831-6839.
[2] Dong Y. Functional Studies of Amino Acid Transporters from the Solute Carrier SLC1 and SLC38 Families[D]. State University of New York at Binghamton, 2024.
[3] Mei B, Xu X, Weng J, et al. Activating astrocytic α2A adrenoceptors in hippocampus reduces glutamate toxicity to attenuate sepsis-associated encephalopathy in mice[J]. Brain, Behavior, and Immunity, 2024, 117: 376-398.
[4] Corbetta C, Di Ianni N, Bruzzone M G, et al. Altered function of the glutamate aspartate transporter GLAST in glioblastoma[J]. bioRxiv, 2018: 287623.
[5] Tirado H A, Balasundaram N, Jacobs J, et al. The EAAT1 aspartate/glutamate transporter is dispensable for acute myeloid leukemia cell growth and response to therapy[J]. Plos one, 2026, 21(2): e0329048.
[6] Corbetta C, Di Ianni N, Bruzzone M G, et al. Altered function of the glutamate–aspartate transporter GLAST, a potential therapeutic target in glioblastoma[J]. International journal of cancer, 2019, 144(10): 2539-2554.
UCPH-101是一种兴奋性氨基酸转运蛋白亚型1（EAAT1）抑制剂，IC50值为0.66μM[1]。UCPH-101是一种慢结合、非竞争性的EAAT1抑制剂，它阻断转运循环中的转位过程，而非其他部分反应[2]。UCPH-101能够阻断右美托咪定（dexmedetomidine）和胍法辛（guanfacine）的神经保护作用[3]。UCPH-101能够通过诱导细胞内谷氨酸积累而导致胶质母细胞瘤细胞死亡，并在胶质瘤小鼠模型中显著提高了生存[4]。
在体外，UCPH-101（20µM）处理小鼠MA9-1细胞和人U937细胞6-24h，均显著升高了两种细胞的凋亡水平，导致了G1期细胞减少、S期及G2/M期细胞相应增加[5]。UCPH-101（10µM）处理GL261-NS细胞、GBM-NS细胞以及星形胶质细胞，显著升高了GL261-NS和GBM-NS细胞的凋亡水平，但不影响星形胶质细胞的凋亡水平[6]。
在体内，UCPH-101（10nmol/μL）通过颅内注射给药治疗胶质瘤细胞异种移植小鼠，显著提高了小鼠存活率，显著破坏了脑胶质瘤的组织结构，显著下调了肿瘤组织中谷氨酸-天冬氨酸转运体（GLAST）的表达水平，显著升高了裂解型Caspase-3的表达水平[6]。
| Cell experiment [1]: | |
Cell lines | Mouse MA9-1 and human U937 cell line |
Preparation Method | Mouse MA9-1 cells and human U937 cells were cultured separately and subsequently treated with UCPH-101 at a final concentration of 20µM. After 24h of treatment, the cells were harvested, and apoptosis was detected via flow cytometry using Annexin V-FITC/PI double staining; a treatment group with 250µM TFB-TBOA was included as a control. An additional group of cells was treated with 20µM UCPH-101 for 6h, followed by fixation and PI staining, to analyze cell cycle distribution via flow cytometry. |
Reaction Conditions | 20µM; 6, 24h |
Applications | Following treatment with 20µM UCPH-101 for 24h, apoptosis increased in both murine MA9-1 cells and human U937 cells; conversely, treatment with 250µM TFB-TBOA did not affect cell viability. Cell cycle analysis revealed that UCPH-101 resulted in a decrease in cells in the G1 phase, accompanied by a corresponding increase in cells in the S and G2/M phases. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6 N mice、CD1 nude mice |
Preparation Method | Five weeks-old female C57BL/6 N (n=10/group for survival studies) and CD1 nude (nude CD1 (HO): CD1-Foxn1nu) mice (n=7/group for survival studies) were intracranially injected with 1×105 GL261-NS or GSCs respectively, in 2μL PBS 1×. The coordinates, with respect to the bregma, were 0.7mm post, 3mm left lateral, 3.5mm deep, and within the nucleus caudatum. Five weeks-old female CD1 nude mice (n=7/group for survival, n=3/group for histolog ical studies); were intracranially injected with 1×105 scram bled or shGLAST GSCs. Five weeks-old female C57BL/6 N mice (n = 7/group for survival analysis; n=4 for histological studies) were injected with 1×105 GL261-NS and treated with 10nmol/μL of UCPH-101 or DMSO as the negative control, 9 days after tumor implantation. For survival studies mice were monitored every day and when suf fering euthanized; for histological studies mice brains were collected and fixed in 4% paraformaldehyde. |
Dosage form | 10nmol/μL; intracranially injected |
Applications | In glioma-bearing mice, a single intratumoral injection of UCPH-101 significantly increased survival by decreasing GLAST expression and inducing apoptosis. |
References: | |
| Cas No. | 1118460-77-7 | SDF | |
| Canonical SMILES | O=C(C1)C2=C(OC(N)=C(C#N)C2C3=CC=C(OC)C=C3)CC1C4=CC=CC5=C4C=CC=C5 | ||
| 分子式 | C27H22N2O3 | 分子量 | 422.48 |
| 溶解度 | DMSO : ≥ 110 mg/mL (260.37 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.367 mL | 11.8349 mL | 23.6698 mL |
| 5 mM | 473.4 μL | 2.367 mL | 4.734 mL |
| 10 mM | 236.7 μL | 1.1835 mL | 2.367 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet